Melanoma trials recruiting in New York

All Melanoma trials nationally

Cities in New York

Recruiting trials in New York

• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
  NCT06413680 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
  NCT07584226 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · New York: New York
• A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
  NCT05970497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
  NCT05053230 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany
• A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
  NCT05562791 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
  NCT06594991 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
  NCT05607095 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Harrison, New York
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
  NCT05859074 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · New York: New York
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
  NCT05837767 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo
• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
  NCT04913285 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Westbury, White Plains
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
  NCT05361174 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: New York
• A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
  NCT06326411 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
  NCT05538130 · Phase: Phase 1 · Ages: 16 Years and older · Sex: All (male and female) · New York: Brewster, Commack, Harrison, Mount Kisco
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
  NCT05355701 · Phase: Phase 1 · Ages: 16 Years and older · Sex: All (male and female) · New York: New York
• ACTengine® IMA203 Combined With mRNA-4203
  NCT06946225 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Adjuvant Tebentafusp in High Risk Ocular Melanoma
  NCT06246149 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: Glens Falls, Jamaica, The Bronx
• Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
  NCT05384496 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Harrison, New York
• BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
  NCT04752826 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
  NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, Mineola, New York
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · New York: Elmhurst, Elmira, Glens Falls, Jamaica
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
  NCT03567889 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Ney York
• Excision of Lymph Node Trial (EXCILYNT) (Mel69)
  NCT05839912 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · New York: Glens Falls, Utica
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
  NCT05428007 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · New York: New York
• Intratumoral N17350 in Advanced Solid Tumors
  NCT07339176 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Bay Shore, Buffalo, Lake Success, Mineola
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
  NCT07015190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Neurocutaneous Melanocytosis Registry
  NCT04548817 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · New York: New York
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
  NCT05059444 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Pancreas Registry and High Risk Registry
  NCT02775461 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · New York: Albany, Brooklyn, Buffalo, Mineola
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Rochester
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · New York: Buffalo, Hempstead, Manhasset, New York
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors
  NCT06060613 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
  NCT07287917 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
  NCT06121180 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New Hyde Park
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
  NCT03947385 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: The Bronx
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Victor
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
  NCT06284590 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Stony Brook
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
  NCT05549297 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · New York: New York
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Brooklyn, Commack, Flushing, Harrison
• The Cancer of the Pancreas Screening-5 CAPS5)Study
  NCT02000089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · New York: Buffalo, Lake Success, Stony Brook, The Bronx
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
  NCT07504796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York